Cronos Group Inc.
CRONHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeCronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. Valued at $955.7M, CRON is a small-cap name in its sector. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Market Cap
$955.7M
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
-63.50
EPS (TTM)
$-0.02
EPS (Fwd)
$-0.04
ROE
-0.3%
ROA
-0.9%
Cash
$831.8M
Total Debt
$1.5M
Free CF
-$51.2M
52W Change
23.9%
Annual Financials
Cash vs Debt
With $831.8M in cash and $1.5M in debt, CRON maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$51.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -0.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $86.7M (2022) to $146.6M (2025), reflecting a 69% increase over the period.
With cash comfortably exceeding debt, CRON has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CRON's risk profile alongside its fundamentals and technical indicators provides a more complete picture.